Limits...
Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.

Tsao CK, Seng S, Oh WK, Galsky MD - Clin Med Insights Oncol (2011)

Bottom Line: However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion.Despite these advances, until recently, only docetaxel had been shown to improve survival in patients with castration-resistant disease, and there has been no standard treatment options available for men with disease progression on docetaxel.In the last year, cabazitaxel, a novel taxane with decreased affinity for ATP-dependent drug efflux pump P-glycoprotein, became the first cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory disease, and has received regulatory approval for treatment in this setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

ABSTRACT
Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion. Despite these advances, until recently, only docetaxel had been shown to improve survival in patients with castration-resistant disease, and there has been no standard treatment options available for men with disease progression on docetaxel. In the last year, cabazitaxel, a novel taxane with decreased affinity for ATP-dependent drug efflux pump P-glycoprotein, became the first cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory disease, and has received regulatory approval for treatment in this setting. In this review, we examine the clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer, as well as rationale and direction of future therapeutic investigation.

No MeSH data available.


Related in: MedlinePlus

Non-hematologic adverse effects of cabazitaxel.14
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3117627&req=5

f2-cmo-1-2011-163: Non-hematologic adverse effects of cabazitaxel.14

Mentions: The adverse events observed in the TROPIC trial are detailed in Figures 1 and 2. Adverse events with cabazitaxel included neutropenia (94%), anemia (97%) and thrombocytopenia (47%). Notably, grade ≥3 neutropenia occurred in 81.7% of patients and 8% experienced neutropenic fever. The most common non-hematologic toxicities observed in the cabazitaxel arm included diarrhea (47%) and fatigue (37%). Only 14% of patients treated with cabazitaxel experience any grade peripheral neuropathy.


Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.

Tsao CK, Seng S, Oh WK, Galsky MD - Clin Med Insights Oncol (2011)

Non-hematologic adverse effects of cabazitaxel.14
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3117627&req=5

f2-cmo-1-2011-163: Non-hematologic adverse effects of cabazitaxel.14
Mentions: The adverse events observed in the TROPIC trial are detailed in Figures 1 and 2. Adverse events with cabazitaxel included neutropenia (94%), anemia (97%) and thrombocytopenia (47%). Notably, grade ≥3 neutropenia occurred in 81.7% of patients and 8% experienced neutropenic fever. The most common non-hematologic toxicities observed in the cabazitaxel arm included diarrhea (47%) and fatigue (37%). Only 14% of patients treated with cabazitaxel experience any grade peripheral neuropathy.

Bottom Line: However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion.Despite these advances, until recently, only docetaxel had been shown to improve survival in patients with castration-resistant disease, and there has been no standard treatment options available for men with disease progression on docetaxel.In the last year, cabazitaxel, a novel taxane with decreased affinity for ATP-dependent drug efflux pump P-glycoprotein, became the first cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory disease, and has received regulatory approval for treatment in this setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.

ABSTRACT
Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion. Despite these advances, until recently, only docetaxel had been shown to improve survival in patients with castration-resistant disease, and there has been no standard treatment options available for men with disease progression on docetaxel. In the last year, cabazitaxel, a novel taxane with decreased affinity for ATP-dependent drug efflux pump P-glycoprotein, became the first cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory disease, and has received regulatory approval for treatment in this setting. In this review, we examine the clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer, as well as rationale and direction of future therapeutic investigation.

No MeSH data available.


Related in: MedlinePlus